Orlando Health Cancer Institute — Orlando, Florida

Public research footprint of Orlando Health Cancer Institute, compiled from the ClinicalTrials.gov public registry.

186

Registered studies

115

Active

Recruiting now

Completed

Stopped or withdrawn

Most-studied conditions

Recurrent Melanoma · Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma · Stage IB Lung Non-Small Cell Carcinoma AJCC v7 · Recurrent Malignant Uterine Corpus Neoplasm

Recently updated registry entries

NCT07227597 — A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People… (Recruiting)
NCT06997497 — A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People… (Recruiting)
NCT04267848 — Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy… (Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Orlando Health Cancer Institute?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 03, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.